New mRNA therapy takes on colorectal cancer in the liver
NCT ID NCT07610707
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new mRNA-based drug called YMN-A02 in 10 people with advanced colorectal cancer that has spread to the liver and has not responded to standard treatments. The drug is designed to help the immune system attack the cancer by producing a CTLA-4 antibody and a TGF-β trap. The main goal is to check safety and find the right dose, while also looking for any signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YMN-A02 (an mRNA-based biologic that produces a CTLA-4 antibody and a TGF-β trap protein)
What this could lead to
If this early trial shows safety and hints of tumor shrinkage, it could point toward a new immunotherapy option for hard-to-treat colorectal cancer with liver spread.
What could go wrong
This is a very early Phase 1 trial with only 10 patients, so it is primarily testing safety, not effectiveness. The treatment may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER WITH LIVER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••